S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
Investing Legend Warns: NVIDIA is a "Delusion" (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
Elon Did It Again: This Could be Bigger than Tesla (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Asian shares fall over China worries, Seoul trading closed for a holiday
Elon Did It Again: This Could be Bigger than Tesla (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
Investing Legend Warns: NVIDIA is a "Delusion" (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
Elon Did It Again: This Could be Bigger than Tesla (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Asian shares fall over China worries, Seoul trading closed for a holiday
Elon Did It Again: This Could be Bigger than Tesla (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
Investing Legend Warns: NVIDIA is a "Delusion" (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
Elon Did It Again: This Could be Bigger than Tesla (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Asian shares fall over China worries, Seoul trading closed for a holiday
Elon Did It Again: This Could be Bigger than Tesla (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
Investing Legend Warns: NVIDIA is a "Delusion" (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
Elon Did It Again: This Could be Bigger than Tesla (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Asian shares fall over China worries, Seoul trading closed for a holiday
Elon Did It Again: This Could be Bigger than Tesla (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
NASDAQ:KRYS

Krystal Biotech (KRYS) Stock Forecast, Price & News

$115.68
+0.33 (+0.29%)
(As of 09/27/2023 ET)
Compare
Today's Range
$114.34
$116.90
50-Day Range
$108.51
$130.22
52-Week Range
$61.11
$132.68
Volume
202,600 shs
Average Volume
260,531 shs
Market Capitalization
$3.24 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$137.57

Krystal Biotech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
18.9% Upside
$137.57 Price Target
Short Interest
Bearish
5.68% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.87
Upright™ Environmental Score
News Sentiment
0.49mentions of Krystal Biotech in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$3.18 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.97) to ($1.12) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

598th out of 976 stocks

Biotechnology Industry

11th out of 18 stocks


KRYS stock logo

About Krystal Biotech (NASDAQ:KRYS) Stock

Krystal Biotech, Inc., a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States. It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis. The company also develops KB408 for Alpha-1 antitrypsin deficiency; and KB301 for aesthetic skin conditions. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

KRYS Price History

KRYS Stock News Headlines

Krystal Biotech (NASDAQ:KRYS) Stock Price Down 2.3%
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Krystal Biotech wins FDA nod to run trial for gene therapy
Krystal Biotech Announces FDA Clearance Of IND For KB408
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Krystal Biotech CEO sells shares worth $6.3M
5 Analysts Have This to Say About Krystal Biotech
Krystal Biotech: FDA Grants Orphan Drug Designation For KB408
Krystal Biotech sells priority review voucher for $100M
Analyst Ratings for Krystal Biotech
Krystal Biotech Shares Tumble 10% on Wider 2Q Loss
See More Headlines
Receive KRYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

KRYS Company Calendar

Last Earnings
8/07/2023
Today
9/27/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KRYS
Fax
N/A
Employees
210
Year Founded
2017

Price Target and Rating

Average Stock Price Forecast
$137.57
High Stock Price Forecast
$154.00
Low Stock Price Forecast
$118.00
Forecasted Upside/Downside
+19.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-139,980,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$20.28 per share

Miscellaneous

Free Float
23,235,000
Market Cap
$3.22 billion
Optionable
Not Optionable
Beta
0.83

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Krish S. Krishnan M.B.A. (Age 58)
    M.S., Founder, Chairman, Pres & CEO
    Comp: $1.07M
  • Ms. Suma M. KrishnanMs. Suma M. Krishnan (Age 58)
    Founder, COO, Pres of R&D and Director
    Comp: $789.92k
  • Ms. Kathryn A. Romano (Age 41)
    Exec. VP & Chief Accounting Officer
    Comp: $528.87k
  • Ms. Meg Dodge
    VP of Investor Relations & Corp. Communications
  • Mr. John Karakkal
    VP of North American Sales & Marketing
  • Mr. Josh Suskin
    Director of HR & Operations
  • Dr. Hubert C. Chen M.D. (Age 54)
    Sr. VP of Clinical Devel.
  • Mr. Laurent Goux
    Sr. VP & GM of Europe
  • Mr. Ram Kamineni
    Sr. VP of CMC & Technical Operations
  • Mr. David Chien
    Sr. VP of Clinical Devel.













KRYS Stock - Frequently Asked Questions

Should I buy or sell Krystal Biotech stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KRYS shares.
View KRYS analyst ratings
or view top-rated stocks.

What is Krystal Biotech's stock price forecast for 2023?

7 analysts have issued 12 month target prices for Krystal Biotech's shares. Their KRYS share price forecasts range from $118.00 to $154.00. On average, they predict the company's stock price to reach $137.57 in the next twelve months. This suggests a possible upside of 19.5% from the stock's current price.
View analysts price targets for KRYS
or view top-rated stocks among Wall Street analysts.

How have KRYS shares performed in 2023?

Krystal Biotech's stock was trading at $79.22 at the start of the year. Since then, KRYS stock has increased by 45.3% and is now trading at $115.11.
View the best growth stocks for 2023 here
.

Are investors shorting Krystal Biotech?

Krystal Biotech saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 1,590,000 shares, an increase of 6.0% from the August 31st total of 1,500,000 shares. Based on an average trading volume of 268,500 shares, the days-to-cover ratio is currently 5.9 days.
View Krystal Biotech's Short Interest
.

When is Krystal Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our KRYS earnings forecast
.

How were Krystal Biotech's earnings last quarter?

Krystal Biotech, Inc. (NASDAQ:KRYS) posted its earnings results on Monday, August, 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.27) by $0.02.

What other stocks do shareholders of Krystal Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).

When did Krystal Biotech IPO?

(KRYS) raised $30 million in an initial public offering on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO.

What is Krystal Biotech's stock symbol?

Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.84%), State Street Corp (3.23%), Point72 Asset Management L.P. (2.00%), Dimensional Fund Advisors LP (1.74%), Credit Suisse AG (1.67%) and Geode Capital Management LLC (1.59%). Insiders that own company stock include Andrew C Orth, Daniel Janney, Dino A Rossi, Kathryn Romano, Krish S Krishnan and Suma Krishnan.
View institutional ownership trends
.

How do I buy shares of Krystal Biotech?

Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Krystal Biotech's stock price today?

One share of KRYS stock can currently be purchased for approximately $115.11.

How much money does Krystal Biotech make?

Krystal Biotech (NASDAQ:KRYS) has a market capitalization of $3.22 billion. The company earns $-139,980,000.00 in net income (profit) each year or ($5.43) on an earnings per share basis.

How many employees does Krystal Biotech have?

The company employs 210 workers across the globe.

How can I contact Krystal Biotech?

Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The official website for the company is www.krystalbio.com. The company can be reached via phone at (412) 586-5830 or via email at arr@lifesciadvisors.com.

This page (NASDAQ:KRYS) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -